Regeneron (REGN) – Litigation
-
Mylan, Celltrion, Apotex said to prevail in IPR patent challenge to Regeneron (REGN) '069 Eyela paten
-
Regeneron (REGN) Contends Novartis (NVS) Eye Syringe Patent Is Invalid - Bloomberg
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to REGN Stock Lookup